James Millis to Graft Rejection
This is a "connection" page, showing publications James Millis has written about Graft Rejection.
Connection Strength
1.422
-
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
Score: 0.313
-
Treatment of liver allograft rejection. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S98-S106.
Score: 0.114
-
Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Transplant Proc. 1998 Jun; 30(4):1435-6.
Score: 0.106
-
Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
Score: 0.096
-
Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
Score: 0.091
-
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012 Jun; 18(6):716-26.
Score: 0.070
-
Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
Score: 0.069
-
Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation. 1989 Jan; 47(1):82-8.
Score: 0.055
-
Risk factors for chronic rejection after pediatric liver transplantation. Transplantation. 2001 Sep 27; 72(6):1098-102.
Score: 0.033
-
Modern immunosuppression. Clin Liver Dis. 2000 Aug; 4(3):619-55, ix.
Score: 0.031
-
Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
Score: 0.026
-
Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. Transplant Proc. 1998 Jun; 30(4):1249-50.
Score: 0.026
-
Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Mar; 30(2):507-8.
Score: 0.026
-
Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis. 1998; 21 Suppl 1:112-8.
Score: 0.026
-
Reversal of accelerated renal allograft rejection with FK 506. Clin Transplant. 1997 Aug; 11(4):251-4.
Score: 0.025
-
Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
Score: 0.024
-
Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation. 1996 Oct 15; 62(7):906-10.
Score: 0.024
-
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transplant. 1996 Aug; 10(4):323-32.
Score: 0.023
-
OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant. 1996 Aug; 10(4):389-95.
Score: 0.023
-
Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
Score: 0.023
-
Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
Score: 0.023
-
Living-donor liver transplantation at UCLA. Am J Surg. 1995 May; 169(5):529-32.
Score: 0.021
-
The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation. 1991 Jan; 51(1):57-62.
Score: 0.016
-
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18; 363(21):2004-14.
Score: 0.016
-
The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation. 1990 Aug; 50(2):189-93.
Score: 0.015
-
The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation. 1990 Aug; 50(2):219-25.
Score: 0.015
-
Preservation of renal function using OKT3 in liver transplant patients. Transplant Proc. 1989 Jun; 21(3):3551-2.
Score: 0.014
-
The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose. Transplant Proc. 1989 Feb; 21(1 Pt 2):2247-8.
Score: 0.014
-
Combined liver and kidney transplantation in children. Transplantation. 2000 Jul 15; 70(1):100-5.
Score: 0.008
-
Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
Score: 0.007
-
Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Jun; 30(4):1538-40.
Score: 0.007
-
An analysis of hepatic retransplantation in children. Transplantation. 1998 May 15; 65(9):1172-8.
Score: 0.007
-
Retransplantation for failed hepatic allografts in children. Transplant Proc. 1997 Feb-Mar; 29(1-2):442-3.
Score: 0.006
-
Small intestine transplantation at the University of California, Los Angeles. Transplant Proc. 1996 Oct; 28(5):2746-7.
Score: 0.006
-
Long-term outcome of kidney-pancreas transplant recipients with good graft function at one year. Transplantation. 1996 Aug 27; 62(4):451-6.
Score: 0.006
-
Late complications in kidney-pancreas transplant recipients. Transplant Proc. 1995 Dec; 27(6):3118.
Score: 0.006
-
Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. Transplantation. 1995 Sep 27; 60(6):554-8.
Score: 0.005
-
Liver transplantation in children. Ann Surg. 1991 Jan; 213(1):48-57.
Score: 0.004
-
The importance of percutaneous liver biopsy in the management of the liver transplant recipient. Transplant Proc. 1988 Feb; 20(1 Suppl 1):682-4.
Score: 0.003